Home page

Hybridoma Screening Platform

Hybridoma technology is an important method for producing monoclonal antibodies. Based on cell fusion, it involves fusing B lymphocytes from immunized animals with myeloma cells, followed by selection using HAT medium and specific screening, and subcloning to obtain monoclonal antibody‑producing cell lines that secrete antibodies capable of specifically recognizing the target antigen. These cell lines are then cultured in vivo or in vitro and subjected to affinity purification to yield the desired monoclonal antibodies.

Preparation process

Preparation principle

B cells can secrete antibodies, and a single B cell clone produces a single type of antibody.
B cells are primary cells that cannot be passaged indefinitely in vitro.

Myeloma cells are a continuously cultured tumor cell line that also originates from B cells, but they do not secrete antibodies themselves. Myeloma cells exhibit an HGPRT enzyme deficiency and cannot survive in HAT medium.

Service Content

Hybridoma screening

Service Items	Content	Cycle	Delivery
Antigen preparation	Antigen design and expression validation, large-scale expression	4 - 8 weeks	Antigen Design and Validation Report, with antigen expression tailored to specific requirements.
Animal immunization	Antigen activity assay (optional), mouse immunization, titer determination	8–10 weeks	Mouse immunization protocol and titer assay report
Fusion, screening, and subcloning	Cell fusion, fusion assay, subcloning, and cryopreservation	6 - 8 weeks	Antibody fusion and subcloning assay report, cryopreserved cell line
Antibody Production, Purification, and Activity Assay	Serum-free antibody cultivation, antibody purification, and antibody activity assay	2 - 4 weeks	Purified antibody, activity assay report

Serum-Free Culture and Adaptation Techniques for Hybridoma Cells

Service Items	Content	Cycle	Delivery
Serum-free culture and purification of antibodies	Serum-free antibody cultivation, antibody purification and purity analysis, and antibody activity assay (optional)	2 - 4 weeks	Purified antibody, antibody purity assay report, and antibody activity assay report (optional)
Serum-free adaptation of hybridoma cells	Direct adaptation of hybridoma cells, gradient adaptation of hybridoma cells, and serum-free expression and purification of adapted cells (optional)	4 - 8 weeks	Cell adaptation report, cryopreserved cells (already adapted), purified antibodies (optional)

Hybridoma antibody sequencing technology

Service Items	Content	Cycle	Delivery
Hybridoma Cell Sequencing	Total RNA extraction from hybridoma cells, 5′-RACE cDNA synthesis, amplification of antibody VH/VL genes, TA cloning and sequencing, and data analysis.	1 week	Sequencing experimental report, antibody sequences, and vectors containing antibody sequences